Ethical challenges: managing oncology drug shortages
- PMID: 23814521
 - PMCID: PMC3595447
 - DOI: 10.1200/JOP.2012.000779
 
Ethical challenges: managing oncology drug shortages
Abstract
This vignette highlights the ethical issues surrounding restricted access to oncology drugs caused by drug shortages. A review of selected literature and a framework for creating institutional guidelines for reacting to shortage is provided.
References
- 
    
- US Senate, Committee on Health Education Labor and Pensions. Washington, DC: US Government Printing Office; 2007. Building a 21st century FDA: Proposals to improve drug safety and innovation (S Hrg. 2007)
 
 - 
    
- ASHP Panel on Drug Product Shortages. Fox ER, Birt A, et al. ASHP guidelines on managing drug product shortages in hospitals and health systems. Am J Health Syst Pharm. 2009;66:1399–1406. - PubMed
 
 - 
    
- Gibson JL, Martin DK, Singer PA. Evidence, economics and ethics: Resource allocation in health services organizations. Healthc Q. 2005;8 50-5 9, 4. - PubMed
 
 - 
    
- Javadzadeh Y, Hamishehkar H. Enhancing percutaneous delivery of methotrexate using different types of surfactants. Colloids Surf B Biointerfaces. 2011;82:422–426. - PubMed
 
 - 
    
- Hahn AF, Feasby TE, Gilbert JJ. Paraparesis following intrathecal chemotherapy. Neurology. 1983;33:1032–1038. - PubMed
 
 
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
